((H&J news, January 16, 2019))From January 6 to 10, 2019, Prof. Meng, President of the company , general manager of American branch John Wang and project manager Xiangxiao Meng went to San Francisco, California to attend the JP Morgan pharmaceutical health industry conference (37th JP Morgan Healthcare Conference). JP Morgan pharmaceutical health industry conference is considered to be an information conference, investment conferences, technology conferences and networking meetings are highly respected by the biomedical industry.

The annual JP Morgan pharmaceutical health industry conference is the largest pharmaceutical industry investment forum in the world. It will bring together industry leaders, high growth company and innovative technology start-ups to share the latest and most advanced technology and innovative ideas in the industry. The JP Morgan pharmaceutical health industry conference is also known as the convergence of industry and capital. The world's top pharmaceutical companies and financial investment institutions and investors are present. The conference has gathered the latest industry frontier topics, especially known as "biotechnology", also known as Bio-super Bowl. The authorized sale of the latest biotechnology has also become an important agenda outside the conference. This conference has led a series of peripheral meetings. For example, eChinaHealth and IQVIA (Ai Kunwei, the original Quintai medicine) jointly organized a deep inspection group and a 4 days summit.

Prof. Meng made a speech about "Significantly Accelerate Global Clinical Trial: China CFDA New Regulation and Our Solution " at the bioengineering road show special meeting. The bioengineering road show special meeting has been held for 11 years. The 2018 meeting attracted more than 450 companies and more than 9000 delegates.